Abstract
This study investigated the clinical management of non small cell lung cancer (NSCLC) patients during the first wave of coronavirus disease 2019 (COVID-19) outbreak in Italy. A 29-questions survey was sent to 95 Italian thoracic oncologists, with 77 % of them declaring significant changes in the outpatients management and treatment. The results of this survey pointed out a significant delay of lung cancer diagnosis along with a relevant reduction of patients’ accrual within clinical trials. Telemedicine emerged as a valid support for patient-healthcare interactions. Therapeutic indications followed the guidelines for adjuvant chemotherapy and concurrent chemo-radiation. Clinical indications to first-line therapies were largely confirmed, while major changes regarded the selection of second line treatment options as well as the management of elderly population.
This work may represent a valid source of information to improve the clinical management of NSCLC patients during second wave of COVID-19 pandemic.
【저자키워드】 COVID-19, survey, lung cancer, SARS‐CoV‐2, Outpatient management, 【초록키워드】 Treatment, coronavirus disease, therapy, COVID-19 pandemic, Diagnosis, clinical trials, Telemedicine, Italy, outbreak, clinical, management, Patient, Clinical management, second wave, information, First wave, change, interactions, Outpatient, Thoracic, Support, reduction, Oncologists, adjuvant chemotherapy, indication, significant delay, Italian, Cell, IMPROVE, significant changes in, investigated, 【제목키워드】 Clinical management, second wave, Italian, Cell, lung cancer patient,